Key result
STEMI patients, especially those with diabetes, had elevated levels of AGEs and sRAGE compared to controls without coronary artery disease, correlating with markers of myocardial injury.
Why the study?
Do levels of AGEs and sRAGE differ in STEMI patients with or without diabetes compared to controls, and do they correlate with markers of myocardial injury?
Observational
Do levels of AGEs and sRAGE differ in STEMI patients with or without diabetes compared to controls, and do they correlate with markers of myocardial injury?
AGEs and sRAGE levels are elevated after STEMI, particularly in diabetic patients, and correlate with markers of myocardial injury and cardiac insufficiency.
The role of advanced glycation end products (AGEs) and its C-terminal truncated receptor (soluble receptor for advanced glycation end products, sRAGE) in ST-segment elevation myocardial infarction (STEMI) patients with or without diabetes is unknown. We compared their levels in patients with and without STEMI, as well as with and without diabetes. A prospective observational study was performed between December 2014 and December 2015. Study group included STEMI patients with coronary artery disease; control group included patients without coronary artery disease. Levels of AGEs and sRAGE were tested on Days 0, 2, and 5 after STEMI. Levels of creatine kinase-MB (CK-MB), cardiac troponin I, and N-terminal pro-brain natriuretic peptide (NT-proBNP) were tested on Days 0, 1, 2, and 3. Patient's diabetic status was determined by medical history or oral glucose tolerance test. Compared to patients in the control group, STEMI patients showed elevated levels of AGEs and sRAGE. In the STEMI group, diabetic patients had higher levels of AGEs and sRAGE compared to nondiabetic patients. The level of AGEs correlated with peak level of CK-MB in the overall population of patients with STEMI and with peak level of NT-proBNP in diabetic patients with STEMI. Levels of AGEs and sRAGE were elevated after STEMI, especially among patients with diabetes. These markers could serve to indicate the severity of myocardial injury and cardiac insufficiency, and play a potential role in predicting the prognosis of patients with STEMI.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2018) conducted an observational in ST-segment elevation myocardial infarction (STEMI). ST-segment elevation myocardial infarction (STEMI) vs. Patients without coronary artery disease was evaluated on Levels of AGEs and sRAGE. STEMI patients, especially those with diabetes, had elevated levels of AGEs and sRAGE compared to controls without coronary artery disease, correlating with markers of myocardial injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: